Search Within

Sridevi Rajeeve

Formats
  1. Meeting Abstract (32)
  2. Journal Article (5)
  3. Review (2)
  4. Correspondence (1)
Groups
  1. Center for Hematologic Malignancies (34)
  2. Department of Medicine (34)
  3. Hematologic Malignancies, Division of (34)
  4. Myeloma (34)
  5. Bone Marrow Transplant (32)
  6. CTCR Scholars (32)

More Groups

People
  1. Sham Mailankody (34)
  2. Saad Usmani (33)
  3. Alexander Lesokhin (31)
  4. Carlyn Rose Tan (31)
  5. Kylee Maclachlan (31)
  6. Malin Hultcrantz (31)

More People

Years
  1. 2025 (2)
  2. 2024 (32)
  3. 2023 (6)
Publications
  1. Blood (20)
  2. Clinical Lymphoma, Myeloma and Leukemia (11)
  3. Blood Advances (2)
  4. Journal of Clinical Oncology (2)
  5. American Journal of Hematology (1)
  6. Blood Cancer Journal (1)

More Publications

Publishers
  1. American Society of Hematology (22)
  2. Elsevier Inc. (11)
  3. American Society of Clinical Oncology (2)
  4. Frontiers Media S.A. (1)
  5. John Wiley & Sons, Inc. (1)
  6. Nature Publishing Group (1)

More Publishers

Results (40)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The landscape of clinical trials for heavily pretreated multiple myeloma: Opportunity for more randomization?
    Correspondence

    Kapur, R.; McCarron, J.; Rajeeve, S.; Mohyuddin, G. R.
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • Addition of elotuzumab to backbone treatment regimens for multiple myeloma: An updated meta-analysis of randomized clinical trials
    Journal Article

    Costa, B. A.; Costa, T. A.; Chagas, G. C. L.; Mouhieddine, T. H.; Richter, J.; Usmani, S. Z.; Mailankody, S.; Rajeeve, S.; Hashmi, H.
    Clinical Lymphoma, Myeloma and Leukemia (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Rajeeve, S.; Costa, B. A.; Jurgens, E. M.; Nishimura, N.; Farzana, T.; Firestone, R. S.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma- Interim efficacy results of a randomized clinical trial
    Meeting Abstract

    Rajeeve, S.; Derkach, A.; Devlin, S. M.; Santos, J.; Przemielewska, A.; Sood, T.; Maclachlan, K. H.; Hashmi, H.; Tan, C. R.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Brown, S.; Devlin, S. M.; Costa, B. A.; Farzana, T.; Jurgens, E. M.; Firestone, R. S.; Nath, K.; Chung, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CAR-tography: Longitudinal mapping of CAR-T toxicities across B-cell malignancies reveals biologically distinct and prognostically relevant toxicity phenotypes
    Meeting Abstract

    Rejeski, K.; Fei, T.; Luna, A.; Alhomoud, M.; Valtis, Y. K.; Nishimura, N.; Gomez-Llobell, M.; Accav, N. G.; Beyar-Katz, O.; Raj, S. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Immune-MRD status informs tumor-MRD outcome prognostication in multiple myeloma patients on lenalidomide maintenance
    Meeting Abstract

    Firestone, R. S.; Simhal, A. K.; McAvoy, D.; Jurgens, E. M.; GarceĢs, J. J.; Nemirovsky, D.; Derkach, A.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Genomic complexity correlates with the degree of marrow independence of malignant plasma cells in the context of extramedullary disease
    Meeting Abstract

    Maclachlan, K. H.; Garces, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C. R.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R. S.; Wang, A. X.; Korde, N.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; more...
    Blood (2024)

    Fulltext@MSK | Save